Central venous access devices are indispensable in modern healthcare but their use come with an inherent patient safety risk [1,2]. Catheter-associated bloodstream infections represent 10%-20% of all nosocomial infections [3], and central line-associated bloodstream infections (CLABSI) are associated with both over-hospitalization and additional costs [4]. Microorganisms can intraluminally access a central venous catheter via its hub, particularly in those containing propofol and parenteral nutrition [5].